The ACTIONED Consortium: integrAted moleCular soluTIons fOr diagNostics and Early Detection
Lead Participant:
QUEEN'S UNIVERSITY BELFAST
Abstract
ACTIONED (integrAted moleCular soluTIons fOr diagNostics and Early Detection) in a consortium of three main partners:
1.National leading experts in genomics/tissue-based cancer diagnostics (The Precision Medicine Centre of Excellence at Queen's University Belfast or PMC)
2.The leading global provider of diagnostic solutions in cancer genomics and tissue diagnostics (Roche)
3.A UK SME with early success in artificial intelligence tools and related analytical frameworks (Sonrai Analytics)
These partners have already worked together before, delivering products that routinely used in diagnostic laboratories in the NHS.
The purpose of this ambitious partnership is to establish, in PMC's state-of-the-art accredited laboratory, all technology and software relating to genomics and tissue-based cancer diagnostics:
a)Genomics, through a technology called Next Generation Sequencing, is the current main driver of personalised medicine to cancer patients.
b)Digital Pathology and Artificial Intelligence is transforming the way we practice traditional pathology, delivering a degree of objectivity and quality-control unknown to date.
Once established, the 3 parties will work on the integration necessary between these two pathways, impacting testing quality/affordability and clinical decision-making.
ACTIONED will provide integration using colorectal cancer as an exemplar, a model to be applicable to all other cancer types, addressing two scenarios of critical unmet need. Firstly, accurate detection of early recurrence in stage II and III colorectal cancer patients, identifying those who will truly benefit from therapy from those who can be spared therapeutic toxicity. Secondly, detection of true early colorectal cancer, addressed as a proof-of-principle.
ACTIONED will drive growth in our economy. Indeed, ACTIONED will be centered in Northern Ireland, providing an analytical/clinical product to be adopted by the NHS as a whole. This will enhance our position as leaders in development of healthcare knowledge and know-how integration at a global scale. Specifically:
a) Sonrai Analytics will develop into a market position of great benefit
b) PMC will become a strong reference laboratory for cancer studies globally.
c) Roche will have a better value for its product.
Finally, ACTIONED will deliver world-leading education through a very successful MSc currently run in Queen's University Belfast.
Strategically, the PMC-Roche-Sonrai partnership within ACTIONED is an unprecedented coalition;
1. Roche's technological and sample commitment
2. Sonrai's capability to improve connectivity and integration between Roche platforms
3, PMC's fully integrated and accredited laboratory framework and strong molecular diagnostic know-how
Together, ACTIONED will show the impact of this integration in our NHS, and improve the lives of our cancer patients.
1.National leading experts in genomics/tissue-based cancer diagnostics (The Precision Medicine Centre of Excellence at Queen's University Belfast or PMC)
2.The leading global provider of diagnostic solutions in cancer genomics and tissue diagnostics (Roche)
3.A UK SME with early success in artificial intelligence tools and related analytical frameworks (Sonrai Analytics)
These partners have already worked together before, delivering products that routinely used in diagnostic laboratories in the NHS.
The purpose of this ambitious partnership is to establish, in PMC's state-of-the-art accredited laboratory, all technology and software relating to genomics and tissue-based cancer diagnostics:
a)Genomics, through a technology called Next Generation Sequencing, is the current main driver of personalised medicine to cancer patients.
b)Digital Pathology and Artificial Intelligence is transforming the way we practice traditional pathology, delivering a degree of objectivity and quality-control unknown to date.
Once established, the 3 parties will work on the integration necessary between these two pathways, impacting testing quality/affordability and clinical decision-making.
ACTIONED will provide integration using colorectal cancer as an exemplar, a model to be applicable to all other cancer types, addressing two scenarios of critical unmet need. Firstly, accurate detection of early recurrence in stage II and III colorectal cancer patients, identifying those who will truly benefit from therapy from those who can be spared therapeutic toxicity. Secondly, detection of true early colorectal cancer, addressed as a proof-of-principle.
ACTIONED will drive growth in our economy. Indeed, ACTIONED will be centered in Northern Ireland, providing an analytical/clinical product to be adopted by the NHS as a whole. This will enhance our position as leaders in development of healthcare knowledge and know-how integration at a global scale. Specifically:
a) Sonrai Analytics will develop into a market position of great benefit
b) PMC will become a strong reference laboratory for cancer studies globally.
c) Roche will have a better value for its product.
Finally, ACTIONED will deliver world-leading education through a very successful MSc currently run in Queen's University Belfast.
Strategically, the PMC-Roche-Sonrai partnership within ACTIONED is an unprecedented coalition;
1. Roche's technological and sample commitment
2. Sonrai's capability to improve connectivity and integration between Roche platforms
3, PMC's fully integrated and accredited laboratory framework and strong molecular diagnostic know-how
Together, ACTIONED will show the impact of this integration in our NHS, and improve the lives of our cancer patients.
Lead Participant | Project Cost | Grant Offer |
|---|---|---|
| QUEEN'S UNIVERSITY BELFAST | £2,556,867 | £ 2,556,867 |
Participant |
||
| ROCHE DIAGNOSTICS LTD | ||
| SONRAI ANALYTICS LTD | £661,000 | £ 462,700 |
| ROCHE DIAGNOSTICS LIMITED | £4,117,761 | |
| QUEEN'S UNIVERSITY OF BELFAST |
People |
ORCID iD |
| David Gonzalez De Castro (Project Manager) |